Advances in Small-Cell Lung Cancer: Recognizing the Potential of Immune Checkpoint Inhibitors and Antibody–Drug Conjugates
Source: Advances in Small-Cell Lung Cancer: Recognizing the Potential of Immune Checkpoint Inhibitors and Antibody–Drug Conjugates

Module

In this CME/CE/CPE-certified activity, Anna F. Farago, MD, PhD; Matthew D. Hellmann, MD; and Taofeek K. Owonikoko, MD, PhD, discuss practical considerations regarding the use of immune checkpoint inhibitors and antibody–drug conjugates in the treatment of patients with small-cell lung cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Determine optimal current strategies for the management of limited-stage and extensive-stage SCLC
  • Discuss recent advances in the understanding of SCLC biology, including the role of the immune system and new therapeutic targets that may lead to improved therapeutic approaches in the near future
  • Review results from clinical trials of immune checkpoint inhibitors and novel antibody–drug conjugates for SCLC to help determine treatment and to identify ongoing trials for suitable patients

Topics covered include:

  • Overview of SCLC
  • Current SCLC Treatment Landscape
  • Immunotherapy in SCLC
  • ADCs in SCLC
  • Other Promising Targeted Therapies in SCLC

 

Faculty

  • Anna F. Farago
    MD, PhD
    Matthew D. Hellmann
    MD
    Taofeek K. Owonikoko
    MD, PhD

Credit Information

  • Release Date:
    October 24, 2017
  • Expiration Date:
    October 23, 2018
  • Physicians:
    maximum of 1.0 AMA PRA Category 1 Credit
  • Registered Nurses:
    1.0 Nursing contact hour
  • Pharmacists:
    1.0 contact hour (0.1 CEUs)

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Anna F. Farago, MD, PhD


Instructor in Medicine
Department of Medicine
Harvard Medical School
Assistant in Medicine
Division of Hematology/Oncology
Department of Medicine
Massachusetts General Hospital
Boston, Massachusetts

Anna F. Farago, MD, PhD, has disclosed that she has received consulting fees from AbbVie and PharmaMar SA and funds for research support paid to her institution from AbbVie, AstraZeneca, Bristol-Myers Squibb, Merck, and PharmaMar SA.

 

Matthew D. Hellmann, MD


Assistant Attending
Thoracic Oncology Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Matthew D. Hellmann, MD, has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Genentech, Janssen, Merck, and Novartis.
 

Taofeek K. Owonikoko, MD, PhD


Professor
Department of Hematology and Medical Oncology
Co-Leader, Thoracic Oncology
Emory University
Atlanta, Georgia

Taofeek K. Owonikoko, MD, PhD, has disclosed that he has received consulting fees from AbbVie/Stemcentrx, Bristol-Myers Squibb, and G1 Therapeutics and funds for research support from AbbVie/Stemcentrx, AstraZeneca, Bristol-Myers Squibb, G1 Therapeutics, Novartis, and United Therapeutics.

 

Staff

Rachael M. Andrie, PhD


Clinical Editor

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.
 

Gordon Kelley, 


Senior Clinical Editor

Gordon Kelley has no real or apparent conflicts of interest to report.
 

Timothy A. Quill, PhD


Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.
 

Kevin Obholz, PhD


Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.
 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Target Audience

This program is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with small-cell lung cancer.


Goal

The goal of this activity is to improve participants’ preparedness to integrate novel immunotherapies into the treatment of patients with small-cell lung cancer.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Determine optimal current strategies for the management of limited-stage and extensive-stage SCLC
  • Discuss recent advances in the understanding of SCLC biology, including the role of the immune system and new therapeutic targets that may lead to improved therapeutic approaches in the near future
  • Review results from clinical trials of immune checkpoint inhibitors and novel antibody–drug conjugates for SCLC to help determine treatment and to identify ongoing trials for suitable patients
 

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Nursing Continuing Education

Accreditation Statement

Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation

This educational activity for 1.0 contact hour is provided by Postgraduate Institute for Medicine.

 

Pharmacist Continuing Education

Accreditation Statement

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - 0809-9999-17-946-H01-P.

Type of Activity: Knowledge

 

Commercial Support


This program is supported by educational grants from AbbVie, and Bristol-Myers Squibb.

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 24, 2017, through October 23, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.